S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
bluebird bio stock is ripe for a 400% institutional short squeeze
Critical asset just had biggest fall on record (Ad)
3 lithium stocks to ride a multi-year cycle
Goldman upgraded Nvidia stock, one metric says it could go higher
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Salesforce stock got a boost. Is it growing off the Nvidia boom?
Autozone stock price is still in the rally zone
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Closing prices for crude oil, gold and other commodities
New highs are coming for Lowe’s stock despite mixed results
NASDAQ:SBTX

Silverback Therapeutics (SBTX) Stock Price, News & Analysis

$8.82
+0.07 (+0.80%)
(As of 02/27/2024 ET)
Today's Range
$8.46
$8.96
50-Day Range
$5.04
$8.75
52-Week Range
$2.80
$8.97
Volume
1.96 million shs
Average Volume
337,931 shs
Market Capitalization
$318.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

SBTX stock logo

About Silverback Therapeutics Stock (NASDAQ:SBTX)

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

SBTX Stock Price History

SBTX Stock News Headlines

ARS Pharmaceuticals Inc (SPRY)
SPRY ARS Pharmaceuticals, Inc.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT
SBTX Silverback Therapeutics, Inc.
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBT
See More Headlines
Receive SBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silverback Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SBTX
Fax
N/A
Employees
83
Year Founded
N/A

Profitability

Net Income
$-89,480,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.41 per share

Miscellaneous

Free Float
23,654,000
Market Cap
$318.03 million
Optionable
Not Optionable
Beta
0.60
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Peter A. Thompson FACP (Age 62)
    M.D., Co-Founder & Chairman of Directors
    Comp: $5.12k
  • Mr. Jeffrey C. Pepe J.D.
    Ph.D., Interim CEO, Gen. Counsel & Corp. Sec.
  • Mr. Russ Hawkinson (Age 63)
    Sr. VP of Fin., Interim CFO, Principal Financial Officer & Principal Accounting Officer
  • Mr. Miguel Arcinas M.B.A.
    VP of Corp. Devel. & Investor Relations
  • Jen More
    Director of HR
  • Ms. Sue Hamke
    Sr. VP of Clinical Operations
  • Mr. Dario Gobunquin CPA
    Sr. Director of Accounting & Controller














SBTX Stock Analysis - Frequently Asked Questions

How have SBTX shares performed in 2024?

Silverback Therapeutics' stock was trading at $5.48 on January 1st, 2024. Since then, SBTX stock has increased by 60.9% and is now trading at $8.82.
View the best growth stocks for 2024 here
.

How were Silverback Therapeutics' earnings last quarter?

Silverback Therapeutics, Inc. (NASDAQ:SBTX) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.65) EPS for the quarter, meeting analysts' consensus estimates of ($0.65).

When did Silverback Therapeutics IPO?

(SBTX) raised $126 million in an initial public offering (IPO) on Friday, December 4th 2020. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, SVB Leerink and Stifel served as the underwriters for the IPO and H.C. Wainwright was co-manager.

How do I buy shares of Silverback Therapeutics?

Shares of SBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SBTX) was last updated on 2/28/2024 by MarketBeat.com Staff